Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Clinical management guidelines on malignant disorders are generally based on data from clinical trials with selected patient cohorts. In Sweden, more than 95% of all patients diagnosed with chronic myeloid leukemia (CML) are reported to the national CML registry, providing unique possibilities to co...

詳細記述

保存先:
書誌詳細
主要な著者: Höglund, Martin, Sandin, Fredrik, Hellström, Karin, Björeman, Mats, Björkholm, Magnus, Brune, Mats, Dreimane, Arta, Ekblom, Marja, Lehmann, Sören, Ljungman, Per, Malm, Claes, Markevärn, Berit, Myhr-Eriksson, Kristina, Ohm, Lotta, Olsson-Strömberg, Ulla, Själander, Anders, Wadenvik, Hans, Simonsson, Bengt, Stenke, Leif, Richter, Johan
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Hematology 2013
主題:
Myeloid Neoplasia
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3744993/
https://ncbi.nlm.nih.gov/pubmed/23843494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-04-495598
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料